Please see below for a list of search results.
The HTA portal is open to collect annual activity data from all establishments licensed under the Human Tissue (Quality and Safety for Human Application) Regulations 2007.
Umbilical cord blood may be collected at the time of birth and stored, so that it is available for potential future treatment of the child or another person.
The European Union Tissue and Cells Directives
Guidance for establishments on meeting HTA licensing requirements for the procurement of tumour samples to be used as a starting material in the manufacture of an Advanced Therapy Medicinal Product (ATMP).
Following the transposition of the European Union Tissues and Cells Directives into UK law via the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended), the HTA (as a risk based regulator) focused on directing its resources to ensuring that those activities that...
Faecal microbiota transplants (FMT) are recognised as an emerging treatment for recurrent Clostridium difficile infections in patients where antibiotic and other lines of treatment have failed.
Designated Individuals have a key role to play in implementing the requirements of the Human Tissue Act. They are the person under whose supervision the licensed activity is authorised to be carried out. They have the primary (legal) responsibility under Section 18 of...
DIs and LHs both play key roles in the licensing arrangements under the Human Tissue Act (2004) and the Q&S Regulations. This section explains the roles and responsibilities of these individuals under the Q&S Regulations. Separate guidance is available on the role of Designated...